Ocugen to Present at the LD 500 Virtual Investor Conference
August 28 2020 - 6:40AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced it will
present at the LD 500 Virtual Investor Conference on Friday,
September 4 at 11 a.m. ET.
Sanjay Subramanian, Chief Financial Officer, will present
virtually to an online audience highlighting Ocugen’s breakthrough
gene therapy platform as well as its novel biologic product
candidate. He will also highlight Ocugen’s lead product
candidate, OCU400, which has the potential to treat many forms of
retinitis pigmentosa and just received its fourth FDA orphan drug
designation. Mr. Subramanian will share Ocugen’s recent
accomplishments and its upcoming planned near and medium-term
milestones.
Presentation
Details:Date: Friday, September 4,
2020Time: 11:00 AM (Eastern Time)Webcast
Link:
https://www.webcaster4.com/Webcast/Page/2019/36995
The LD 500 will take place September 1-4, 2020 and will feature
some of the most prominent companies in the micro-cap world,
alongside interviews and keynotes with small-cap leaders.
About Ocugen, Inc. Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial Officer ir@ocugen.com +1
484-328-4698
Media Contact:LaVoieHealthScienceEmmie
Twomblyetwombly@lavoiehealthscience.com+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024